SAGE-324

Sage Therapeutics and Biogen's SAGE-324 shows no significant benefit in Phase II KINETIC 2 study for essential tremor treatment.

Sage Therapeutics' dalzanemdor failed in the Phase II DIMENSION trial for Huntington's disease, leading to the discontinuation of its development.

Sage Therapeutics' dalzanemdor (SAGE-718) failed to meet key goals in a Phase 2 study for cognitive impairment in Huntington's disease, leading to the program's discontinuation.

Sage Therapeutics is focused on the launch of Zurzuvae for postpartum depression, with early metrics tracking in line with expectations.

The Phase 2 KINETIC 2 study of SAGE-324 (BIIB124) did not meet its primary endpoint of demonstrating a statistically significant dose-response relationship in essential tremor patients.